Inspired by the richness of nature - the venom of tropical sea snails
we have created a unique cosmeceutical, Miorelaxant Magic.
The secret of Miorelaxant Magic is a unique, globally exclusive ingredient with myorelaxant properties, meaning it relaxes facial mimic muscles, obtained through biotechnological methods in a laboratory.
The cream's production process utilized the latest technological advancements – cosmetic product tests were conducted on a skin model, and application tests were performed on a group of volunteers.
A revolution in daily skincare with the strongest possible anti-wrinkle action, enriched with unique nourishing ingredients, biomimetic peptides, and an innovative skin penetration promoter.
The cosmeceutical Miorelaxant Magic is an effective, unique, yet non-invasive and safe way to achieve a younger appearance.
Recombinant proprietary conotoxin
Our proprietary active substance – recombinant conotoxin – is obtained using E. coli bacterial strains. The conotoxin we produce is identical to that originally generated by marine snails of the genus Conus.
Recombinant conotoxin is produced as a fusion protein from recombinant genes, i.e., molecules of DNA – deoxyribonucleic acid, which is the most common carrier of genetic information. Gene expression in the bacterial cell is possible through the use of special expression vectors containing a strong promoter that enables the production of large quantities of protein in the recipient cell.
Imaging the expression of the gene encoding recombinant conotoxin
To separate the DNA fragments obtained in our laboratory based on their size and charge, we use the gel electrophoresis technique.
DNA molecules carry a negative charge on their surface, thanks to which they move through an agarose or polyacrylamide gel towards the positive electrode under the influence of an applied current. To identify the size of the DNA molecules, a molecular weight marker is loaded onto the gel, which migrates through the gel in parallel with the analyzed sample and allows one to determine whether the desired product has been obtained.
Culture of an E. coli strain expressing recombinant conotoxin
After achieving expression of the gene encoding conotoxin, culture conditions for the host strain producing our active substance are selected. Both eukaryotic and prokaryotic expression systems are used for the overproduction of recombinant proteins.
The most commonly used system for protein overproduction, both on a laboratory and industrial scale, is the prokaryotic system. In our case, this system is based on E. coli bacteria.
Purification of recombinant conotoxin by affinity chromatography methods
We confirm the presence of the recombinant conotoxin in the cultures using SDS-PAGE protein gels, after which the active substance of our cosmeceutical is purified using affinity chromatography methods. The peptide purification process is multi-stage, which ensures that we eliminate all bacterial contaminants. The next step is to select dialysis conditions to obtain a correctly folded peptide that possesses 3 disulfide bridges stabilizing its structure.
Confirmation of the biological activity of recombinant conotoxin in oocyte cells
The final stage of the production of the active ingredient in the Miorelaxant Magic cosmeceutical is the in vitro determination of the recombinant conotoxin's activity and its incorporation into a cream formulation that ensures the conotoxin's stability and activity, guaranteeing its efficacy. We verify the conotoxin's activity using the patch-clamp method on live oocyte cell lines that exhibit overexpression of human sodium channels specific to conotoxins. This study confirmed the myorelaxant activity of the recombinant conotoxin we produced.
Klinicznie udowodnione Clinically proven
Nauka, której nie da się podważyć Science you can't argue with
Randomizowane badanie z podwójnym zaślepieniem i grupą placebo. 60 ochotników, 6 miesięcy obserwacji, wyniki potwierdzone przez niezależny panel ekspertów. Randomized, double-blind, placebo-controlled clinical trial. 60 volunteers, 6 months of observation, results confirmed by an independent expert panel.
vs placebo po 6 miesiącach better aesthetic effect
vs placebo after 6 months
w spoczynku vs placebo higher satisfaction
at rest vs placebo
podczas mimiki vs placebo higher satisfaction
during facial expressions vs placebo
Efekt estetyczny w czasie — ocena niezależnych ekspertów Aesthetic effect over time — independent expert evaluation
Obie grupy otrzymały zabieg z toksyną botulinową. Następnie przez 6 miesięcy stosowały krem — jedna z konotoksyną, druga bez (placebo). Od dnia 90. różnica rośnie na korzyść konotoksyny. Both groups received a botulinum toxin treatment. Then for 6 months they used a cream — one with conotoxin, the other without (placebo). From day 90, the difference grows in favor of conotoxin.
Różnice statystycznie istotne (p<0.05) od dnia 90. W dniu 180 p≈0.0000 — najwyższa istotność. Skala 1–5, ocena efektu estetycznego przez niezależny panel ekspertów na podstawie medycznej dokumentacji fotograficznej. Statistically significant differences (p<0.05) from day 90. At day 180, p≈0.0000 — highest significance. Scale 1–5, aesthetic effect evaluation by an independent expert panel based on medical photographic documentation.
test t-Studenta, p<0.001 od dnia 135 Student's t-test, p<0.001 from day 135Efekty konotoksyny Conotoxin effects
vs placebo, ocena ekspertów, 180 dni vs placebo, expert evaluation, 180 days
istotne od dnia 105, brak efektu w placebo significant from day 105, no effect in placebo
istotne od dnia 60, brak efektu w placebo significant from day 60, no effect in placebo
Efekty bazy kremowej Cream base effects
pomiary kutometryczne, obie grupy, 180 dni corneometer measurements, both groups, 180 days
pomiary kutometryczne, 180 dni, p<0.001 corneometer measurements, 180 days, p<0.001
obie grupy porównywalnie — efekt bazy both groups comparable — base formula effect
Profil bezpieczeństwa >95% Safety profile >95%
Reakcje skórne u mniej niż 5% uczestników, przypisane iniekcji toksyny botulinowej. Objawy uboczne (swędzenie, pieczenie, zdrętwienie) występowały częściej w grupie placebo niż w grupie stosującej krem z konotoksyną. Skin reactions in fewer than 5% of participants, attributed to the botulinum toxin injection. Side effects (itching, burning, numbness) occurred more frequently in the placebo group than in the conotoxin cream group.
Badanie: K-LAB Badania i Rozwój, Gdynia · Standard ISO 14155:2020 · Główny badacz: dr n. med. Paweł Kubik · 60 ochotników (30+30), wiek 30–68 lat · Randomizacja + podwójne zaślepienie · Toksyna botulinowa 20j. + krem 2×/dziennie przez 180 dni · Pomiary: kutometr Multi Skin Test Centre 1000, dokumentacja foto FotoMedicus · Pozytywna opinia Komisji Bioetycznej przy OIL w Gdańsku · REP/1/4/S4B/K-LAB/2023/PL Study: K-LAB Research & Development, Gdynia, Poland · ISO 14155:2020 standard · Principal investigator: Paweł Kubik, MD, PhD · 60 volunteers (30+30), age 30–68 · Randomized + double-blinded · Botulinum toxin 20u + cream 2×/day for 180 days · Measurements: corneometer Multi Skin Test Centre 1000, FotoMedicus photo documentation · Bioethics Committee approval, Gdańsk · REP/1/4/S4B/K-LAB/2023/PL
BEFORE AND AFTER
Results of application tests after 28 days of using Miorelaxant Magic cream twice a day by a group of 60 volunteers.
-
Improved skin condition
Good hydration: 80%
Increased skin softness: 71%
Increased skin firmness: 71%
Increased skin radiance: 58%
Reduction in the visibility of wrinkles: 42%
Even skin tone: 42%
Reduced visibility of pores: 42%
Reduction in sebum secretion: 47% -
Reduced and softened wrinkles
Reduced wrinkle depth: 42%
Reduced wrinkle length: 36%
Reduced number of wrinkles: 32%
Suitable consistency: 95%
Suitable absorption: 87%
Suitable color: 96%
Ease of application: 93%
Noticeable difference in skin condition: 65% -
Product safety test reports